Samsung Biologics Co. said it plans to carve its business into a contract drug manufacturer and a holding firm which will ...

Samsung Biologics Co., a biotech arm of South Korea's Samsung Group, said Thursday it plans to spin off its biosimilar ...

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

Samsung Biologics, the biotech arm of Samsung Group, announced Thursday that it will spin off its biosimilar operations into ...

Samsung Biologics spins off Samsung Bioepis Holdings to enhance competitiveness Samsung Bioepis Holdings aims to streamline ...

South Korean contract development and manufacturing organisation (CDMO) Samsung Biologics marks another contract milestone as the company announces two high-value deals totalling £897 million ...

Recorded Q1'25 consolidated revenue of KRW 1.3 trillion Recorded Q1'25 consolidated operating profit of KRW 486.7 billion Company expected to maintain steady growth momentum in 2025 driven by ...

Samsung Biologics Co., a biotech arm of South Korea's Samsung Group, said Thursday it plans to spin off its biosimilar ...

Samsung Biologics reported consolidated revenue of KRW 1.3 trillion in the first quarter of 2025, mainly driven by the stable ramp-up of Plant 4 while maintaining the full utilization of Plants 1 ...

Samsung Biologics, a biotech arm of South Korea's Samsung Group, said Thursday it plans to spin off its biosimilar ...